Mackenzie Financial
MYGN icon

Mackenzie Financial’s Myriad Genetics MYGN Stock Holding History

Mackenzie Financial’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-210,697
Closed -$7.62M – 838
2017
Q3 		$7.62M Hold
210,697
– – 0.04% 295
2017
Q2 		$5.44M Buy
+210,697
New +$4.47M 0.03% 303

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Mackenzie Financial's MYGN Position: Q4 2017 in Review

Mackenzie Financial sold out of Myriad Genetics (MYGN) in Q4 2017, closing a stake of 210,697 shares — an estimated $7.62M sold.

Mackenzie Financial first reported a position in MYGN in Q2 2017 and held it in 2 quarters. The position peaked at $7.62M in Q3 2017. 250 funds tracked by Wall St. Rank hold MYGN as of Q4 2017.

  • Mackenzie Financial reported no remaining Myriad Genetics position as of Q4 2017 after selling out during the quarter.
  • Mackenzie Financial sold 210,697 Myriad Genetics shares in Q4 2017, an estimated $7.62M.
  • Mackenzie Financial first reported a position in Myriad Genetics in Q2 2017 and held it in 2 quarters.
  • Mackenzie Financial's Myriad Genetics position peaked at $7.62M in Q3 2017.
  • 250 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2017.

Based on Mackenzie Financial's 13F filing for Q4 2017, filed 13 Feb 2018.